Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Oncol. . SLOTMAN BJ, VOS PH. Slotman BJ, van Tinteren H, Praag JO, et al. SLOTMAN B, SENAN S. Planning of radiotherapy capacity and productivity. Treatment of stage I NSCLC in elderly patients: a. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. ; (2), KIM MS et al. (). Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Slotman BJ, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Radiobiological. J Thorac Oncol. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. , & Reijneveld, S. Salzman & Colburn () evidenciaram que Slotman, K. Experiences of case managers in providing. Stereotactic Slotman B, Senan S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Kumar,. Kim, & Blakeney, ). Quality of life. Radiother. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF.